Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 or 5282 South Commerce Drive, Suite D292 Murray, Utah 84107 (435) 645-2000 (Address of principal executive offices) (Registrant's telephone number, including area code) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 001-34941 (Commission fil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 Nevada 37-1454128 State or other jurisdiction of incorporation (IRS Employer Identification No.) 5282 South Commerce Drive, Suite D292 Murray, Utah 84107 (435) 645-2000 (Address of principal executive offices) (Registrant's telephone number, including area code) or ☐ TRANSITION REPORT ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number: 001-39553 AMESITE INC. (Exact name of registrant as specified in its charter) | Delaware | 82-3431718 | | --- | --- ...

For Immediate Release Exhibit 99.1 BENEFICIENT REPORTS RESULTS FOR FOURTH QUARTER & FISCAL YEAR ENDED MARCH 31, 2025 • Reported investments with a fair value of $291.4 million, from $329.1 million at the end of our prior fiscal year, which served as collateral for Ben Liquidity's net loan portfolio of $244.1 million and $256.2 million, at March 31, 2025 and 2024, respectively. • Subsequent to March 31, 2025, completed three additional Primary Capital transactions with initial value totaling $11.8 million wi ...

Exhibit 99.1 IDT Corporation Reports Fourth Quarter and Fiscal Year 2025 Results 4Q25 Gross Profit +12% to $114 million; FY 2025 Gross Profit +14% to $446 million 4Q25 Income from Operations +9% to $22 million; Adjusted EBITDA +33% to $33 million FY 2025 Income from Operations +55% to $100 million; Adjusted EBITDA +43% to $129 million, an IDT record 4Q25 EPS of $0.67 and Non-GAAP EPS of $0.76; FY 2025 EPS of $3.01 and Non-GAAP EPS of $3.19 NEWARK, NJ — September 29, 2025: IDT Corporation (NYSE: IDT), a glob ...

EXHIBIT 99.1 Worthington Steel Reports First Quarter Fiscal 2026 Results Quarterly Results COLUMBUS, Ohio, September 24, 2025 – Worthington Steel, Inc. (NYSE: WS), a market-leading, value-added metals processing company, today reported financial results for the fiscal 2026 first quarter ended August 31, 2025. First Quarter Highlights (all comparisons to the first quarter of fiscal 2025): "Worthington Steel is off to a strong start in fiscal 2026 driven by disciplined execution in a soft market, resulting in ...

FOR THE FISCAL YEAR ENDED JUNE 30, 2025 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36081 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) (State or other jurisdiction of incorporation or organization) DELAWARE 76-0674577 (I.R.S. Employer Identification No.) 1 CONTROLS DRIVE, SHELTON, CONNECTICUT, 06484 (Address of principal exe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934 For the transition period from To Commission file number: 000-31203 LESAKA TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction (IRS Employer of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-40388 ANEBULO PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 85-1170950 (State or other jurisdiction of incorporation or organization) 10 ...

收入和利润（同比环比） - FY2025第四季度净收入为3.287亿美元（53亿南非兰特），同比增长38%（以兰特计）[7] - FY2025全年净收入为8200万美元（15亿南非兰特），同比增长47%（以兰特计）[7] - 调整后净利润为1036.1万美元，较2024财年的287.8万美元增长260.1%[37] 净亏损（同比环比） - FY2025第四季度净亏损8750万美元（16亿南非兰特），同比增长386%（以兰特计），主要因非现金费用和一次性交易成本[7] - FY2025全年净亏损2880万美元（5.15亿南非兰特），同比增长452%（以兰特计）[7] - 2025财年第四季度归属于Lesaka的GAAP净亏损为2894.8万美元，而2024财年同期为503.5万美元[33] - 2025财年全年归属于Lesaka的GAAP净亏损为8763.4万美元，而2024财年为1744万美元[33] - 公司2025财年净亏损为8750.4万美元，较2024财年的1744万美元亏损扩大401.7%[37][39] - 季度净亏损从503.5万美元扩大至2205.8万美元[45] - 年度净亏损从1744万美元扩大至8750.4万美元[46] 调整后EBITDA（同比环比） - FY2025第四季度调整后EBITDA为5070万美元（9.222亿南非兰特），同比增长33%（以兰特计）[7] - FY2025全年调整后EBITDA为1670万美元（3.056亿南非兰特），同比增长61%（以兰特计）[7] - 2025财年第四季度集团调整后EBITDA为1671.8万美元，相比2024财年同期的1025.8万美元增长63%[33] - 2025财年全年集团调整后EBITDA为5068.8万美元，相比2024财年的3693.6万美元增长37%[33] 调整后每股收益（同比环比） - FY2025第四季度调整后每股收益为0.13美元（2.29南非兰特），同比增长187%（以兰特计）[7] - FY2025全年调整后每股收益为0.05美元（0.99南非兰特），同比增长211%（以兰特计）[7] - 按调整后基准计算，2025财年第四季度每股基本收益为0.05美元，而2024财年同期为0.02美元[36] 每股基本亏损（同比环比） - 基本每股亏损从2024财年的0.28美元扩大至1.14美元，增幅307.1%[37][39] - 季度每股基本亏损从0.08美元改善至0.04美元[45] - 年度每股基本亏损从0.26美元扩大至0.90美元[46] 未来业绩指引 - FY2026调整后每股收益预期至少为4.60南非兰特，同比增长超过100%[4][8] - FY2026预期调整后EBITDA增长至少35%[4] 非现金费用和一次性项目 - 2025财年第四季度无形资产摊销（PPA）为779.6万美元，而2024财年同期为365.7万美元[33] - 2025财年第四季度股权证券公允价值变动带来收益567.6万美元[33] - 2025财年第四季度确认一次性减值损失1886.3万美元[33] - 2025财年第四季度一次性项目总额为1322.7万美元，主要包含收购相关交易成本1298.5万美元[33] - 股权证券公允价值变动带来4929.4万美元收益[37] - 无形资产摊销费用达1561万美元，较2024财年的1054.3万美元增长48.1%[37] - 股权激励费用为955万美元，较2024财年的791.1万美元增长20.7%[37] 现金流表现 - 经营现金流净流出912.1万美元，较2024财年流入2878.9万美元恶化131.7%[41] - 投资活动现金流净流出1134.2万美元，较2024财年流出1641.5万美元改善30.9%[41] - 期末现金及等价物为7663.9万美元，较2024财年末6591.8万美元增长16.3%[41] 成本和费用（同比环比） - 利息支出达2145.3万美元，较2024财年的1893.2万美元增长13.3%[39] 其他财务数据 - 当前财务信息为初步未经审计结果，最终审计结果将包含在截至2025年6月30日财年的10-K表格文件中[32]